ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
125.034,63
1,36%
S&P 500
5.770,20
0,55%
US Dollar vs BRL
5,7879
0,00%
Bitcoin
85.965,91
-0,22%
Brent Oil
70,235
0,00%
As Melhores Corretoras Online
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. NextCure Inc (NXTC)

  7. NextCure Inc (NXTC) Notícias

NXTC

NextCure (NXTC)

NextCure Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:NXTC
DataHoraFonteTítuloCódigoCompanhia
06/03/202518:05GlobeNewswire Inc.NextCure Provides Business Update and Reports Full Year 2024 Financial ResultsNASDAQ:NXTCNextCure Inc
14/02/202515:40Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:NXTCNextCure Inc
06/02/202518:16Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NXTCNextCure Inc
03/02/202520:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NXTCNextCure Inc
03/02/202518:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NXTCNextCure Inc
10/01/202510:05GlobeNewswire Inc.NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple CancersNASDAQ:NXTCNextCure Inc
10/12/202410:05GlobeNewswire Inc.NextCure Announces Acceptance of IND Application for LNCB74NASDAQ:NXTCNextCure Inc
26/11/202409:00GlobeNewswire Inc.NextCure to Participate in the 36th Annual Piper Sandler Healthcare ConferenceNASDAQ:NXTCNextCure Inc
19/11/202410:05GlobeNewswire Inc.Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis ImperfectaNASDAQ:NXTCNextCure Inc
14/11/202420:59Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:NXTCNextCure Inc
07/11/202418:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NXTCNextCure Inc
07/11/202418:05GlobeNewswire Inc.NextCure Provides Business Update and Reports Third Quarter 2024 Financial ResultsNASDAQ:NXTCNextCure Inc
05/11/202418:05GlobeNewswire Inc.NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual MeetingNASDAQ:NXTCNextCure Inc
04/10/202410:05GlobeNewswire Inc.NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual MeetingNASDAQ:NXTCNextCure Inc
16/09/202409:05GlobeNewswire Inc.NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024NASDAQ:NXTCNextCure Inc
01/08/202417:05GlobeNewswire Inc.NextCure Provides Business Update and Reports Second Quarter 2024 Financial ResultsNASDAQ:NXTCNextCure Inc
20/06/202417:10GlobeNewswire Inc.NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceNASDAQ:NXTCNextCure Inc
30/05/202417:05GlobeNewswire Inc.NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024NASDAQ:NXTCNextCure Inc
02/05/202417:05GlobeNewswire Inc.NextCure Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:NXTCNextCure Inc
24/04/202417:05GlobeNewswire Inc.NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024NASDAQ:NXTCNextCure Inc
08/04/202408:00GlobeNewswire Inc.NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024NASDAQ:NXTCNextCure Inc
04/04/202408:05GlobeNewswire Inc.NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory BoardNASDAQ:NXTCNextCure Inc
02/04/202408:00GlobeNewswire Inc.NextCure to Present at 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:NXTCNextCure Inc
21/03/202409:55GlobeNewswire Inc.NextCure Provides Business Update and Reports Full Year 2023 Financial ResultsNASDAQ:NXTCNextCure Inc
05/03/202410:05GlobeNewswire Inc.NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science AdvancesNASDAQ:NXTCNextCure Inc
18/01/202418:05GlobeNewswire Inc.NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway DisordersNASDAQ:NXTCNextCure Inc
21/12/202309:05GlobeNewswire Inc.NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord InjuryNASDAQ:NXTCNextCure Inc
14/12/202308:45GlobeNewswire Inc.NextCure Provides Year-End Clinical Pipeline UpdatesNASDAQ:NXTCNextCure Inc
20/11/202309:00GlobeNewswire Inc.NextCure to Present at the 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:NXTCNextCure Inc
15/11/202318:05GlobeNewswire Inc.NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AMLNASDAQ:NXTCNextCure Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:NXTC

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios